1,191 results on '"Guglielmelli, P."'
Search Results
2. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
3. Unveiling Chirality: Exploring Nature's Blueprint for Engineering Nanostructured Materials
4. Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study
5. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience
6. Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasms
7. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
8. Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting
9. All-Optical tunability of metalenses infiltrated with liquid crystals
10. Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib
11. Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study
12. Restoring of Interhemispheric Symmetry in Patients With Stroke Following Bilateral or Unilateral Robot-Assisted Upper-Limb Rehabilitation: A Pilot Randomized Controlled Trial
13. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience
14. Unveiling chirality: Exploring nature’s blueprint for engineering plasmonic materials
15. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
16. Role of the Human Serum Albumin Protein Corona in the Antimicrobial and Photothermal Activity of Metallic Nanoparticles against Escherichia coli Bacteria
17. Incidence of blast phase in myelofibrosis according to anemia severity
18. Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model
19. Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
20. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
21. P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
22. P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
23. P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS
24. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
25. Breakthrough infections in MPN-COVID vaccinated patients
26. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
27. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
28. Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
29. Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia
30. Cross section measurements of $^{155,157}$Gd(n,$\gamma$) induced by thermal and epithermal neutrons
31. Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
32. Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
33. Second versus first wave of COVID-19 in patients with MPN
34. A parallel classification strategy to simultaneous control elbow, wrist, and hand movements
35. Breakthrough infections in MPN-COVID vaccinated patients
36. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
37. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
38. Intrinsic Superchirality in Planar Plasmonic Metasurfaces.
39. A parallel classification strategy to simultaneous control elbow, wrist, and hand movements
40. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
41. Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
42. Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
43. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms
44. Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10/L to
45. A Multiaxial Rehabilitation Programme for Workers with COVID-19 Sequelae Using a Conventional and Technological-Robotic Approach: The Proposal of INAIL and Fondazione Don Carlo Gnocchi
46. Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study
47. Long-term follow-up of recovered MPN patients with COVID-19
48. When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy
49. Platypnea-orthodeoxia syndrome as a consequence of SARS-CoV-2 pneumonia: an uncommon case of dyspnea
50. Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.